Navigation Links
Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting

ion of a novel small Bruey-Sedano, molecule Smac mimetic compound PhD, (SM-164) and agonist TRAIL-R Ascenta monoclonal Abs (mapatumumab & Therapeutics lexatumumab). Human Genome Sciences --------- --------- ---------------------------------- -------------- Wednesday 8:30am- In vivo efficacy of AT-101, an Dajun Yang, April 18 12pm orally active pan-Bcl-2 family MD, PhD, protein inhibitor in combination Ascenta with the ErbB1 tyrosine kinase Therapeutics inhibitor erlotinib (Tarceva(R)) ---------------------------------- -------------- A novel pan inhibitor of Bcl-2 and Xiongwen Mcl-1, apogossypolone (ApoG2), Zhang, MD, with superior stability and PhD improved activity against human Ascenta leukemia and lymphoma cells. Therapeutics --------- --------- ---------------------------------- -------------- Date Time Session Type/Location Abstract # ---------- --------- ----------------------------------- ------------- Saturday 4:15pm Alternative approaches to small Oral April 14 molecule drug discovery protein- Presentation protein interaction in Petree D ---------- --------- ----------------------------------- ------------- Sunday 8am-12pm Experimental and Molecular Poster in April 15 Therapeutics 4 Exhibit Hall. Poster s
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

Post Your Comments:
(Date:12/3/2009)...c. 3 Radiology imaging leader MEDR...ration capabilities at the November 2009 Radiology...t.PACS(TM) product, enabling the first radiology ...t release in the company,s newly branded Certegra...://www.newscom.com/cgi-bin/prnh/20091203/NE20631 ...
(Date:12/3/2009).... 3 Wound Management...rapidly growing provider of specialty medical prod... Industry Representative Association (HIRA) to ser...ing representative to market the company,s core Ce...IRA will market and sell Wound Management Technolo...
(Date:12/3/2009)...re-FirstCall/ -- Cardium Therapeutics (NYSE Amex: ...diary, Tissue Repair Company, submitted a 510(k) p...d Drug Administration (FDA) seeking marketing clea...sed on positive data from the Company,s recently c...submission with the FDA covers Excellagen XL(TM) ...
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 1Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 2Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 1SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 10Combo Treatment May Ease Depression After Stroke 53891 1Combo Treatment May Ease Depression After Stroke 53891 2
(Date:12/4/2009).... 4 , ,What: Humana ( ht... health benefits provider, is introd...s.com ), a senior-friendly dance pad, ...ues., Dec. 8 at 1 p.m. The festive ...n to the public, will feature Dancetown, ...
(Date:12/4/2009)...PRNewswire-FirstCall/ -- MedClean Technologies, In...Company has entered into a preferred stock purchas...ware limited liability company, doing business as... to the Purchase Agreement, MedClean will receive ...agreed to sell up to 750 shares of its Series C Pr...
(Date:12/4/2009)...Newswire/ -- PLUS Diagnostics announced today th...y services with the launch of a national hematolog... company,s expansion from a regional laboratory to...ering diagnostic services across a full range of s... now hematology/oncology. ,, PLUS Diagnostics ...
(Date:12/4/2009)...RNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc...5,012,334 for the first quarter ended September 30...ear. Operating income and net income for the quar...a 70% decrease over the same period last year. ,... sector sales. This trend is expected to continue...
(Date:12/4/2009)...swire/ -- The National Cancer Institute has awarde...Hutchinson Cancer Research Center to become the na...vice Contact Center. ,, The move will create 60...ng the size of its current CIS workforce - once th...is scheduled for March 15, 2010. The Seattle CIS c...
Breaking Medicine News(10 mins):Health News:Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2
... Madhya Pradesh may raise the retirement age of me... doctors posted in interior areas// in order to pr...etter health and medical services to people is a p...ce will also be provided to them," Chief Minister ...
... Dubai: With a motive of enabling women the best p...s about to commence a free breast cancer screening... The tests will enable all women in the emirate, U...ter treatment outcomes. Dr Hajer Al Hosani,...
... AMA President, Dr Mukesh Haikerwal, said today th...rocesses for assessing the skills// and experience... confidence in the quality of medicine in Australi... and fair to ensure the community gets expert medi...
... American scientists have identified a single prot... the development of diabetes//. Researchers at...calcineurin, is vital to the proper functioning of...0 genes that had already been linked to diabetes. ...
... According to a study conducted at the University ...evelopment of chronic pain following breast cancer...ve surgery, and severe post-operative pain. ...ths, near the breast, next to armpit and in the up...
... A team of scientists from Bristol University has ...e energy levels in living heart cells that will ai...rt attack. The scientists expect this techni... Chemistry. Dr Elinor Griffiths and her team...
Other Medicine News:Health News:Consistent National Standards For Assessment Of Overseas Trained Doctors A Priority 2Health News:Post-Operative Pain in Breast Cancer Surgery 2Health News:A glowing energy measure for heart cells 2
TME 228 TS
TME 63 TC
TME 66 S
TME 64 S-3
Medicine Products: